甲灭酸对 IKs 分子复合物的双重作用

IF 6.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Magnus Chan, Marc Pourrier, Jodene Eldstrom, Harutyun Sahakyan, Vitya Vardanyan, David Fedida
{"title":"甲灭酸对 IKs 分子复合物的双重作用","authors":"Magnus Chan, Marc Pourrier, Jodene Eldstrom, Harutyun Sahakyan, Vitya Vardanyan, David Fedida","doi":"10.1111/bph.17389","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Mutations in both KCNQ1 and KCNE1, which together form the cardiac I<sub>Ks</sub> current, are associated with inherited conditions such as long and short QT syndromes. Mefenamic acid, a non-steroidal anti-inflammatory drug, is an I<sub>Ks</sub> potentiator and may be utilised as an archetype to design therapeutically useful I<sub>Ks</sub> agonists. However, here we show that mefenamic acid can also act as an I<sub>Ks</sub> inhibitor, and our data reveal its dual effects on KCNQ1/KCNE1 channels.</p><p><strong>Experimental approach: </strong>Effects of mefenamic acid on wild type (WT) and mutant KCNQ1/KCNE1 channels expressed in tsA201 cells were studied using whole cell patch clamp. Molecular dynamics simulations were used to determine trajectory clustering.</p><p><strong>Key results: </strong>Mefenamic acid inhibits WT I<sub>Ks</sub> at high concentrations while preserving some attributes of current potentiation. Inhibitory actions of mefenamic acid are unmasked at lower drug concentrations by KCNE1 and KCNQ1 mutations in the mefenamic acid binding pocket, at the extracellular end of KCNE1 and in the KCNQ1 S6 helix. Mefenamic acid does not inhibit KCNQ1 in the absence of KCNE1 but inhibits I<sub>Ks</sub> current in a concentration-dependent manner in the mutant channels. Inhibition involves modulation of pore kinetics and/or voltage sensor domain-pore coupling in WT and in the KCNE1 E43C mutant.</p><p><strong>Conclusion and implications: </strong>This work highlights the importance of structural motifs at the extracellular inter-subunit interface of KCNQ1 and KCNE1 channels, and their interactions, in determining the nature of drug effects on the I<sub>Ks</sub> channel complex and has important implications for treating patients with specific long QT mutations.</p>","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":" ","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dual effects of mefenamic acid on the I<sub>Ks</sub> molecular complex.\",\"authors\":\"Magnus Chan, Marc Pourrier, Jodene Eldstrom, Harutyun Sahakyan, Vitya Vardanyan, David Fedida\",\"doi\":\"10.1111/bph.17389\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and purpose: </strong>Mutations in both KCNQ1 and KCNE1, which together form the cardiac I<sub>Ks</sub> current, are associated with inherited conditions such as long and short QT syndromes. Mefenamic acid, a non-steroidal anti-inflammatory drug, is an I<sub>Ks</sub> potentiator and may be utilised as an archetype to design therapeutically useful I<sub>Ks</sub> agonists. However, here we show that mefenamic acid can also act as an I<sub>Ks</sub> inhibitor, and our data reveal its dual effects on KCNQ1/KCNE1 channels.</p><p><strong>Experimental approach: </strong>Effects of mefenamic acid on wild type (WT) and mutant KCNQ1/KCNE1 channels expressed in tsA201 cells were studied using whole cell patch clamp. Molecular dynamics simulations were used to determine trajectory clustering.</p><p><strong>Key results: </strong>Mefenamic acid inhibits WT I<sub>Ks</sub> at high concentrations while preserving some attributes of current potentiation. Inhibitory actions of mefenamic acid are unmasked at lower drug concentrations by KCNE1 and KCNQ1 mutations in the mefenamic acid binding pocket, at the extracellular end of KCNE1 and in the KCNQ1 S6 helix. Mefenamic acid does not inhibit KCNQ1 in the absence of KCNE1 but inhibits I<sub>Ks</sub> current in a concentration-dependent manner in the mutant channels. Inhibition involves modulation of pore kinetics and/or voltage sensor domain-pore coupling in WT and in the KCNE1 E43C mutant.</p><p><strong>Conclusion and implications: </strong>This work highlights the importance of structural motifs at the extracellular inter-subunit interface of KCNQ1 and KCNE1 channels, and their interactions, in determining the nature of drug effects on the I<sub>Ks</sub> channel complex and has important implications for treating patients with specific long QT mutations.</p>\",\"PeriodicalId\":9262,\"journal\":{\"name\":\"British Journal of Pharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/bph.17389\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bph.17389","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:KCNQ1 和 KCNE1 共同构成心脏 IKs 电流,它们的突变与长 QT 综合征和短 QT 综合征等遗传性疾病有关。非甾体抗炎药甲灭酸是一种 IKs 增效剂,可用作设计具有治疗作用的 IKs 激动剂的原型。然而,在这里我们发现甲灭酸也可以作为一种 IKs 抑制剂,我们的数据揭示了它对 KCNQ1/KCNE1 通道的双重作用:实验方法:我们使用全细胞膜片钳研究了甲灭酸对在 tsA201 细胞中表达的野生型(WT)和突变型 KCNQ1/KCNE1 通道的影响。分子动力学模拟用于确定轨迹聚类:甲灭酸在高浓度下抑制 WT IKs,同时保留了电流电位的某些属性。在甲灭酸结合袋、KCNE1 细胞外端和 KCNQ1 S6 螺旋中的 KCNE1 和 KCNQ1 突变可在较低药物浓度下解除甲灭酸的抑制作用。在没有 KCNE1 的情况下,甲灭酸不会抑制 KCNQ1,但会以浓度依赖的方式抑制突变通道中的 IKs 电流。在 WT 和 KCNE1 E43C 突变体中,抑制涉及孔动力学和/或电压传感器结构域-孔耦合的调节:这项研究强调了 KCNQ1 和 KCNE1 通道亚基间胞外基质界面的结构基团及其相互作用在决定药物对 IKs 通道复合物影响性质方面的重要性,对治疗特定长 QT 突变患者具有重要意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Dual effects of mefenamic acid on the IKs molecular complex.

Background and purpose: Mutations in both KCNQ1 and KCNE1, which together form the cardiac IKs current, are associated with inherited conditions such as long and short QT syndromes. Mefenamic acid, a non-steroidal anti-inflammatory drug, is an IKs potentiator and may be utilised as an archetype to design therapeutically useful IKs agonists. However, here we show that mefenamic acid can also act as an IKs inhibitor, and our data reveal its dual effects on KCNQ1/KCNE1 channels.

Experimental approach: Effects of mefenamic acid on wild type (WT) and mutant KCNQ1/KCNE1 channels expressed in tsA201 cells were studied using whole cell patch clamp. Molecular dynamics simulations were used to determine trajectory clustering.

Key results: Mefenamic acid inhibits WT IKs at high concentrations while preserving some attributes of current potentiation. Inhibitory actions of mefenamic acid are unmasked at lower drug concentrations by KCNE1 and KCNQ1 mutations in the mefenamic acid binding pocket, at the extracellular end of KCNE1 and in the KCNQ1 S6 helix. Mefenamic acid does not inhibit KCNQ1 in the absence of KCNE1 but inhibits IKs current in a concentration-dependent manner in the mutant channels. Inhibition involves modulation of pore kinetics and/or voltage sensor domain-pore coupling in WT and in the KCNE1 E43C mutant.

Conclusion and implications: This work highlights the importance of structural motifs at the extracellular inter-subunit interface of KCNQ1 and KCNE1 channels, and their interactions, in determining the nature of drug effects on the IKs channel complex and has important implications for treating patients with specific long QT mutations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
15.40
自引率
12.30%
发文量
270
审稿时长
2.0 months
期刊介绍: The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries. Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues. In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信